Current Legal Status: CJC-1295 in 2026
CJC-1295 occupies a favorable legal position — it remains available through both compounding pharmacies and research chemical vendors. It has avoided the FDA Category 2 restrictions that hit BPC-157 and the compounding battles surrounding semaglutide.
Federal Legal Status
| Status | CJC-1295 |
|---|---|
| FDA-approved | No |
| Category 2 restricted | No |
| Controlled substance | No |
| Available from compounding pharmacies | Yes (with Rx) |
| Available as research chemical | Yes |
| WADA prohibited | Yes |
Why CJC-1295 Is Still Compoundable
CJC-1295 has avoided Category 2 for several reasons:
- Clinical precedent — CJC-1295 has been prescribed by anti-aging and wellness clinics for over a decade with a documented safety track record
- No competing pharmaceutical product — unlike semaglutide (competing with Ozempic/Wegovy), there is no brand-name CJC-1295 product lobbying for enforcement
- Lower regulatory profile — the FDA’s enforcement focus has been on high-visibility compounds (BPC-157, GLP-1s), not the broader GH peptide market
- Combination prescribing — CJC-1295 is almost always prescribed with Ipamorelin as a combination product, which has established clinical protocols
Access Pathways
1. Compounding Pharmacy (Prescription Required)
The most common route for clinical use:
| Feature | Details |
|---|---|
| Typical product | CJC-1295 (no DAC) + Ipamorelin combination vial |
| Prescription | Required from MD, DO, NP, or PA |
| Cost | $150-350/month |
| Quality | Pharmacy-grade, USP standards |
| Availability | 503A and 503B pharmacies nationwide |
Advantages: Pharmaceutical quality, doctor supervision, pre-mixed for convenience, precise dosing.
Considerations: Requires prescription, higher cost than research-grade, availability could change if FDA takes action.
2. Research Chemical
| Feature | Details |
|---|---|
| Product | CJC-1295 (with or without DAC) as lyophilized powder |
| Prescription | Not required |
| Cost | $30-60 per vial (2mg) |
| Quality | Varies — require CoA verification |
| Availability | Widely available from research vendors |
3. Telehealth + Compounding
Many telehealth platforms now offer CJC-1295/Ipamorelin protocols:
- Online consultation → prescription → shipped from partner compounding pharmacy
- Cost typically $200-400/month including consultation
- Convenient for people without a local anti-aging clinic
The DAC Question
CJC-1295 comes in two variants with identical legal status but different pharmacological profiles:
| Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|---|
| Half-life | 6-8 days | ~30 minutes |
| GH release pattern | Sustained elevation | Pulsatile (natural pattern) |
| Injection frequency | 1-2x per week | 1-3x daily |
| Clinical preference | Less common | More common (paired with Ipamorelin) |
| Research availability | Available | Available |
| Compounding availability | Less common | Standard |
| Legal status | Same | Same |
Which version to choose is a protocol decision, not a legal one. Most clinics use the no-DAC version because pulsatile GH release mimics the body’s natural pattern and has a better safety profile. See the CJC-1295 Protocol for detailed guidance.
WADA Prohibition
CJC-1295 is prohibited under WADA:
- Category: S2 — Growth Hormone Releasing Factors
- Timing: Prohibited at all times
- Both versions: DAC and no-DAC are both prohibited
- Combination: CJC-1295 + Ipamorelin is also prohibited
- Detection: Detectable via urine testing for days to weeks after last injection
Risk of Future Restrictions
Category 2 Possibility
CJC-1295 is among the peptides most likely to face Category 2 classification if the FDA expands its restrictions:
Higher risk factors:
- Widely compounded and prescribed
- No FDA approval or clinical trial data meeting FDA standards
- Growing market visibility
Lower risk factors:
- No competing pharmaceutical product pushing for enforcement
- Established clinical use history
- FDA enforcement bandwidth focused elsewhere
Best estimate: CJC-1295 compounding access will likely remain available through 2026, but users should be aware that restrictions could come with limited warning, similar to BPC-157.
Practical Preparation
If you rely on compounded CJC-1295:
- Build a relationship with a research chemical vendor as a backup
- Learn reconstitution — research-grade CJC-1295 requires mixing with bacteriostatic water
- Stock reasonably — a 2-3 month supply buffer is prudent
- Monitor FDA announcements — Category 2 decisions are published on the FDA website
Related Resources
- CJC-1295 Protocol — dosing, timing, and administration
- Growth Hormone Peptides Compared — CJC-1295 vs alternatives
- Ipamorelin Legal Status — legal status of the common pairing
- Growth Hormone Stack — CJC-1295 + Ipamorelin combination protocol
- Peptide Legality & FDA Status Guide — complete overview
Frequently Asked Questions
Is CJC-1295 legal in 2026? +
Yes. CJC-1295 is legal to purchase as a research chemical and is available from some compounding pharmacies. It is not FDA-approved, not a controlled substance, and has not been placed on the FDA's Category 2 list. It remains one of the more accessible GH peptides through both research and compounding channels.
Can I get CJC-1295 from a compounding pharmacy? +
Yes, as of early 2026. CJC-1295 (typically combined with Ipamorelin) is still available from some 503A and 503B compounding pharmacies with a prescription. Unlike BPC-157, CJC-1295 has not been placed on the FDA's Category 2 restricted list. However, compounding availability may change as the FDA continues to review peptide compounds.
What is the difference between CJC-1295 with DAC and without DAC? +
CJC-1295 with DAC (Drug Affinity Complex) has a longer half-life (6-8 days) and creates sustained GH elevation. CJC-1295 without DAC (also called Modified GRF 1-29) has a shorter half-life (30 minutes) and produces pulsatile GH release that mimics natural patterns. Most clinics prescribe the no-DAC version combined with Ipamorelin because pulsatile release is considered safer and more physiological. Both versions have the same legal status.
Is CJC-1295 banned in sports? +
Yes. CJC-1295 is on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth hormone releasing factor. It is prohibited at all times. Both the DAC and no-DAC versions are banned. The combination of CJC-1295 + Ipamorelin is also prohibited.
Could CJC-1295 be added to the FDA Category 2 list? +
Possible. The FDA is reviewing additional peptides for Category 2 classification. CJC-1295 is a candidate because it is widely compounded and prescribed by anti-aging clinics. However, no formal action has been announced as of early 2026. If added, compounding pharmacies would no longer be able to produce it, though research chemical availability would be unaffected.